Aspen Pharmacare

Aspen Pharmacare Holdings Limited
Public (JSE: APN)
JSE Limited
Industry Health care, Pharmaceutical industry
Founded 1850,[1] public 1997.[1]
Headquarters Durban, South Africa[2]
Key people
 Stephen Saad (Group Chief Executive)[3]
Revenue IncreaseR12,400,000,000 (FY 2011)[4]
Profit IncreaseR5,600,000,000 (FY 2011)[4]
Total assets IncreaseR26,800,000,000 (FY 2011)[4]
Total equity IncreaseR13,300,000,000 (FY 2011)[4]
Owner Stephen Saad
Number of employees
 6,319[5]
Website www.aspenpharma.com

Aspen Pharmacare Holdings Limited is a multinational South African holding company for pharmaceutical concerns,[3] and the largest drug company in Africa.[6][7]

History

Activity in HIV/AIDS-related medicines

After complaints of anticompetitive activities by Boehringer Ingelheim and GlaxoSmithKline in 2003, Aspen was granted licenses from the companies to create generic versions of antiretrovirals (ARV) for use in the Sub-Saharan portion of Africa.[8] At the time, Aspen was already the largest generic medicine distributor in South Africa.[8] Subsequent inspections by international organizations led to a rapid increase in distribution capabilities, primarily though integration with alliance partners.[8] The company's efforts led to expanded access to affordable treatments for HIV/AIDS.[9]

Products

The company supplies more than 650 branded medicines, specializing in generics and treatments for HIV/AIDS and tuberculosis.[7]

References

  1. 1 2 "Timeline of the Aspen Group's evolution". Aspen Annual Report 2011. Aspen Holdings. Retrieved 11 May 2015.
  2. ↑ "Global presence". Aspen Annual Report 2011. Aspen Holdings. Retrieved 11 May 2015.
  3. 1 2 "APN Profile & Executives—Aspen Pharmacare Holdings Ltd". Bloomberg. Retrieved 11 May 2015.
  4. 1 2 3 4 "Group statement of comprehensive income". Aspen Holdings. Retrieved 11 May 2015.
  5. ↑ "Notes to the Group Annual Financial Statements". Aspen Annual Report 2011. Aspen Holdings. Retrieved 11 May 2015. Full-time employees 5168, Part-time employees 1151
  6. ↑ Simeon Bennett; Michael Cohen (21 May 2010). "Aspen Pharmacare Offers to Buy Australia's Sigma Pharma for $1.23 Billion". Bloomberg News.
  7. 1 2 Tenu Avafia; Jonathan Berger; Trudi Hartzenberg (1 January 2009). "8. The ability to utilize TRIPS flexibilities in sub-Saharan African countries". In Ricardo Meléndez-Ortiz; Pedro Roffe. Intellectual Property and Sustainable Development: Development Agendas in a Changing World. Edward Elgar Publishing. pp. 177–8. ISBN 978-1-84844-645-8. Retrieved 30 June 2012 – via Google Books.
  8. 1 2 3 Patrick Lumumba Osewe; Yvonne Korkoi Nkrumah; Emmanuel K. Sackey (15 June 2008). Improving Access to HIV/AIDS Medicines in Africa: Trade-Related Aspects of Intellectual Property Rights (TRIPS) Flexibilities Utilization. World Bank Publications. pp. 35–9. ISBN 978-0-8213-7544-0. Retrieved 30 June 2012 – via Google Books.
  9. ↑ Karen Maas; Frank Boons (30 April 2010). "7. CSR as a strategic activity". In Céline Louche; Samuel O. Idowu; Walter Leal Filho. Innovative CSR: From Risk Management to Value Creation. Greenleaf Publishing. p. 158. ISBN 978-1-906093-35-8. Retrieved 30 June 2012.
This article is issued from Wikipedia - version of the 10/29/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.